SEC Form 4 · accession 0001144204-18-054109
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua Silverman
Director
Period of report
Oct 16, 2018
Accepted (ET)
Oct 17, 2018 · 8:54 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 16, 2018 | A | 4,106 | $0.00 | A | 17,221 | D | |
| Common Stock | holding | — | — | — | 153,333 | I | By JNS Holdings Group LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.